[DE] NEUE SUBSTITUIERTE STICKSTOFFHALTIGE HETEROBICYCLEN UND DEREN VERWENDUNG ALS FAKTOR XA INHIBITOREN [EN] NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS [FR] NOUVEAUX COMPOSES HETEROBICYCLIQUES AZOTES SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU FACTEUR XA
[DE] NEUE SUBSTITUIERTE STICKSTOFFHALTIGE HETEROBICYCLEN UND DEREN VERWENDUNG ALS FAKTOR XA INHIBITOREN [EN] NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS [FR] NOUVEAUX COMPOSES HETEROBICYCLIQUES AZOTES SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU FACTEUR XA
Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions
申请人:Priepke Henning
公开号:US20050107409A1
公开(公告)日:2005-05-19
The present invention relates to new aromatic bicyclic compounds of general formula
wherein Ar, X, Y and Z and R
1
to R
3
are defined as in claim
1,
the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof, as well as their preparation and their use as pharmaceutical compositions. The compounds of the above general formula I have valuable pharmacological properties, particularly an antithrombotic activity and a factor Xa-inhibiting activity.
Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions
申请人:Boehringer Ingelheim Pharma GmbH & Co. KG
公开号:US20040176603A1
公开(公告)日:2004-09-09
The present invention relates to new substituted nitrogen-containing heterobicyclic compounds of general formula
1
wherein B, X
1
to X
3
and R
1
to R
5
are defined as in claim
1,
the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.
The compounds of the above general formula I as well as the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, and their stereoisomers have valuable pharmacological properties, particularly an antithrombotic activity and a factor Xa-inhibiting activity.
SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
申请人:Priepke Henning
公开号:US20090181958A1
公开(公告)日:2009-07-16
The present invention relates to new substituted nitrogen-containing heterobicyclic compounds of general formula
wherein B, X
1
to X
3
and R
1
to R
5
are defined as in claim
1
, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.
The compounds of the above general formula I as well as the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, and their stereoisomers have valuable pharmacological properties, particularly an antithrombotic activity and a factor Xa-inhibiting activity.
[DE] NEUE SUBSTITUIERTE STICKSTOFFHALTIGE HETEROBICYCLEN UND DEREN VERWENDUNG ALS FAKTOR XA INHIBITOREN<br/>[EN] NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS<br/>[FR] NOUVEAUX COMPOSES HETEROBICYCLIQUES AZOTES SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU FACTEUR XA
申请人:BOEHRINGER INGELHEIM PHARMA
公开号:WO2004058743A1
公开(公告)日:2004-07-15
Gegenstand der vorliegenden Erfindung sind neue substituierte stickstoffhaltige Heterobicyclen der allgemeinen Formel (I), in der B, X1 bis X3 und R1 bis R5 wie in Anspruch 1 definiert sind, deren Tautomere, deren Enantiomere, deren Diastereomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, welche wertvolle Eigenschaften aufweisen. Die Verbindungen der obigen allgemeinen Formel (I) sowie deren Tautomere, deren Enantiomere, deren Diastereomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, und deren Stereoisomere weisen wertvolle pharmakologische Eigenschaften auf, insbesondere eine antithrombotische Wirkung und eine Faktor Xa-inhibierende Wirkung.